Allogene Therapeutics, Inc. (ALLO) and Arbor Biotechnologies, Inc. on Tuesday announced that they have entered into a non-exclusive, global gene editing licensing agreement. The licensing will allow Allogene to use Arbor's innovative CRISPR gene-editing technology in its next-generation AlloCAR T platform for the treatment of autoimmune diseases also known as AID.
Allogene also stated that its first investigational AlloCAR T product designed for AID is currently in development and is expected to enter Phase 1 clinical trials in early 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.